Journal of International Medical Research · 2016 · 27 citations · 19 references
MedicineCardiologyRadiologyCardiothoracic RadiologyClinical CardiologyUltrasonographyAortic DiseaseAortic Valve DiseaseCardiac BiomarkersCardiovascular DiseaseCardiovascular PathologyValvular Heart DiseaseAortic Imaging BiomarkersAortic Valve Calcification ProgressionAortic Valve Disease PrognosisCross-sectional Incidence StudyIntracardiac EchocardiographyProprotein ConvertasesValve Calcification AssessmentValvular Calcification
OBJECTIVE: To investigate the possible association between plasma proprotein convertase subtilisin/kexin type 9 (PCSK9) and the incidence and severity of calcific aortic valve disease (CAVD). METHODS: This prospective, cross sectional study involved patients with and without (controls) aortic valve calcification diagnosed by transthoracic echocardiography and dual source computed tomography (DSCT) scan. Aortic valves calcification scores were calculated from DSCT scans and patients were graded: grade 1, no calcification; grade 2, mildly calcified; grade 3, moderately calcified; grade 4, heavily calcified. Plasma PCSK9 levels were measured using an enzyme-linked immunosorbent assay. RESULTS: Forty patients were grade 1 (controls), 32 were grade 2, 48 were grade 3 and 32 were grade 4. Plasma levels of PCSK9 were significantly different between the four groups and the highest value was observed in the patients with grade 2 calcification. Only low-density lipoprotein cholesterol and lipoprotein (Lp)(a) were associated with the severity of CAVD. Regression analysis showed that age, Lp(a) and PCSK9 were independent predictors of CAVD. CONCLUSION: Data from this cross sectional study in a small sample of patients showed that plasma PCSK9 was correlated with the presence of CAVD but not its severity.
19
Intensive Lipid Lowering with Simvastatin and Ezetimibe in Aortic Stenosis
Anne B. Rossebø, Terje R. Pedersen, Kurt Boman et al. · New England Journal of Medicine · 2008 · 1.6K citations · Full text
Effect of Lipid Lowering With Rosuvastatin on Progression of Aortic Stenosis
Kwan L. Chan, Koon Teo, Jean G. Dumesnil et al. · Circulation · 2010 · 795 citations
A 52-Week Placebo-Controlled Trial of Evolocumab in Hyperlipidemia
Dirk Blom, Tomas Hala, Michael A. Bolognese et al. · New England Journal of Medicine · 2014 · 713 citations · Full text